(S)-4-(2-(2-(2-(dimethylamino)ethoxy)ethylamino)-8-(1-hydroxypropan-2-ylamino)quinazolin-6-yl)-5-ethyl-2-fluorophenol

ID: ALA5094089

Chembl Id: CHEMBL5094089

PubChem CID: 166632168

Max Phase: Preclinical

Molecular Formula: C25H34FN5O3

Molecular Weight: 471.58

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  CCc1cc(O)c(F)cc1-c1cc(N[C@@H](C)CO)c2nc(NCCOCCN(C)C)ncc2c1

Standard InChI:  InChI=1S/C25H34FN5O3/c1-5-17-12-23(33)21(26)13-20(17)18-10-19-14-28-25(27-6-8-34-9-7-31(3)4)30-24(19)22(11-18)29-16(2)15-32/h10-14,16,29,32-33H,5-9,15H2,1-4H3,(H,27,28,30)/t16-/m0/s1

Standard InChI Key:  XXYVYULKAZLNBS-INIZCTEOSA-N

Alternative Forms

  1. Parent:

    ALA5094089

    ---

Associated Targets(Human)

AURKB Tchem Serine/threonine-protein kinase Aurora-B (6805 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
JAK1 Tclin Tyrosine-protein kinase JAK1 (8569 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
JAK2 Tclin Tyrosine-protein kinase JAK2 (12915 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
JAK3 Tclin Tyrosine-protein kinase JAK3 (8349 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TYK2 Tclin Tyrosine-protein kinase TYK2 (5029 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KDR Tclin Vascular endothelial growth factor receptor 2 (20924 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
JAK3 Tclin JAK3/JAK1 (270 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
JAK1 Tclin JAK1/JAK2/TYK2 (47 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 471.58Molecular Weight (Monoisotopic): 471.2646AlogP: 3.49#Rotatable Bonds: 12
Polar Surface Area: 102.77Molecular Species: BASEHBA: 8HBD: 4
#RO5 Violations: 0HBA (Lipinski): 8HBD (Lipinski): 4#RO5 Violations (Lipinski): 0
CX Acidic pKa: 8.29CX Basic pKa: 9.00CX LogP: 2.34CX LogD: 1.73
Aromatic Rings: 3Heavy Atoms: 34QED Weighted: 0.30Np Likeness Score: -0.75

References

1. Wellaway CR, Baldwin IR, Bamborough P, Barker D, Bartholomew MA, Chung CW, Dümpelfeld B, Evans JP, Fazakerley NJ, Homes P, Keeling SP, Lewell XQ, McNab FW, Morley J, Needham D, Neu M, van Oosterhout AJM, Pal A, Reinhard FBM, Rianjongdee F, Robertson CM, Rowland P, Shah RR, Sherriff EB, Sloan LA, Teague S, Thomas DA, Wellaway N, Wojno-Picon J, Woolven JM, Coe DM..  (2022)  Investigation of Janus Kinase (JAK) Inhibitors for Lung Delivery and the Importance of Aldehyde Oxidase Metabolism.,  65  (1.0): [PMID:34928601] [10.1021/acs.jmedchem.1c01765]

Source